Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)

Storebø, Ole Jakob; Storm, Maja Rosenberg Overby; Ribeiro, Johanne Pereira; Skoog, Maria; Groth, Camilla; Callesen, Henriette E; Schaug, Julie Perrine; Rasmussen, Pernille Darling; Huus, Christel-Mie Lykke; Zwi, Morris; Kirubakaran, Richard; Simonsen, Erik; Gluud, Christian

doi:10.1002/14651858.cd009885.pub3

Cited by 18 publications

(23 citation statements)

References 812 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A search for trial registers: After we have found our cohort, Storebø et al 2023 [1] will be used during screening to see if a trial publication was found in the previous data collection, either as included or excluded. Screening will be performed by two independent researchers reaching a consensus on inclusion or exclusion.…”

Section: Methodology 1 Cohort Selectionmentioning

confidence: 99%

“…-If included in Storebø et al 2023 [1], data will be extracted via that reference -Scan for tabular summary results -Scan for publications uploaded by sponsor/investigator or automatically indexed by registry -Enter clinical trial identifier in Google Scholar and search first 2 pages for potential match by title.…”

Section: First Literature Searchmentioning

confidence: 99%

“…This is a follow-up study on a recent systematic review by Storebø and colleagues [1]. This review suggested potential benefits of methylphenidate on ADHD core symptom severity as well as general behavior, but the certainty of the evidence for the use of methylphenidate for ADHD in children and adolescents was found to be low or very low in all 212 randomised clinical trials [1]. Furthermore, most trials were quite small, with the average sample size being only 70 children.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Methylphenidate for Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) – unpublished or unregistered randomised clinical trials

Kristensen,

Gluud,

Storebø

2023

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction This is a follow-up study on a recent systematic review by Storeboe et al. [1]. It aims to investigate research waste and publication bias in randomized clinical studies investigating the use of methylphenidate for children and adolescent with ADHD. Method The method used includes an initial cohort selection from searching Clinicaltrials.gov and the EUCTR with the following inclusion criteria: Use of methylphenidate either as stand-alone or part of psychological treatment for ADHD, randomised clinical trials, any dosage, any delivery method and at least 75% children and adolescents with ages less than 18. Results The primary objective is to assess how many randomised clinical trials of methylphenidate on children and adolescents with ADHD are registered in protocol databases, but never published in academic literature or as tabular summary results. The number of participants included in these trials is a secondary objective. The tertiary objective is to assess the time from registry to publication of randomised clinical trials of methylphenidate on children and adolescents with ADHD in either a journal or as summary results, and the number of participants in these trials. The cutoff time for a publication to be considered timely published will be 12 months, as per FDAA guidelines [3]

show abstract

Section: Methodology 1 Cohort Selectionmentioning

confidence: 99%

Section: First Literature Searchmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methylphenidate for Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) – unpublished or unregistered randomised clinical trials

Kristensen,

Gluud,

Storebø

2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Attention deficit hyperactivity disorder (ADHD) is a psychiatric condition characterized by three main behavioural deficits: impulsivity, hyperactivity and lack of attention (Mueller et al, 2017; Storebø et al, 2023). These are observed during early childhood and often persist into adult life.…”

Section: Introductionmentioning

confidence: 99%

“…Indirect dopaminergic agonists such as AMPH, methylphenidate and modafinil are widely used in the clinic to treat cognitive deficits (Mueller et al, 2017; Storebø et al, 2023). These drugs are also commonly used in preclinical studies to test the predictive validity of behavioural tasks for assessing pharmacologically induced enhancement in cognitive functions, particularly attention and impulsivity (Tomlinson et al, 2014; MacQueen et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

The D1 receptor agonist SKF38393 improves waiting impulsivity in a baseline dependent manner

Abdulkader,

Gigg

2023

Preprint

View full text Add to dashboard Cite

Rationale: ADHD is a neuropsychiatric disorder characterized by inattention and impulsivity. Stimulants such as amphetamine are the most common pharmacological treatment for ADHD. However, such stimulants have substantial abuse and dependence risk. For example, stimulants (smart pills) are commonly used by students to enhance academic performance. Therefore, there is a pressing need for new therapeutic agents. Dysfunction of the dopaminergic system has been associated with ADHD symptoms. D1 receptors play an important role in the cognitive enhancing effects of stimulants and thus may provide a therapeutic target. Previous pre-clinical studies have shown that selective activation of D1 receptors improves sustained attention in the 5C-CPT without improving waiting impulsivity. The present study extends this work to investigate the effect of selective activation of D1 receptors on waiting impulsivity as measured by 5C-CPT. Objective: The aim of the present experiment was to compare the effects of the selective D1 receptor agonist SKF 38393 to a standard ADHD treatment (amphetamine) on waiting impulsivity in the 5C-CPT under extended inter-trial intervals. Methods: Adult female Lister hooded rats were trained to criterion in the 5C-CPT. After rats were able to distinguish target from non-target trials the effects of the selective D1 receptor agonist SKF 38393 (2-6 mg/kg) or amphetamine (0.1-0.4 mg/kg) were investigated under behavioural manipulations to challenge inhibitory response control and, to a lesser extent, attentional resources. The traditional method of analysing drug effects on group data (or sub-groups of high and low performers) was compared with correlational analysis using Oldham method to determine if drug treatment affected waiting impulsivity in a baseline dependent manner. Results: The highest dose of SKF 38393 selectively improved waiting impulsivity in a baseline dependent manner without having a significant effect on sustained attention or response inhibition. The two highest doses of amphetamine improved waiting impulsivity in a baseline dependent manner without having a significant effect on sustained attention and response inhibition. Conclusions: The effects of AMPH on waiting impulsivity further supports the predictive validity of 5C-CPT. In addition, this study taken together with previous studies which report pro attentional effects of D1 receptor agonists suggests that D1 selective agonists could be therapeutically beneficial in ADHD patients. Clinical trials are needed to confirm these effects. This is the first study to take advantage of the variation in individual baseline waiting impulsivity to demonstrate the presence of a rate-dependent relationship between baseline waiting impulsivity and magnitude of improvement following stimulant or non-stimulant medications. Oldham correlation method may present an opportunity to enhance the translational value of research in the preclinical laboratory to the clinic. Furthermore, these findings further support the ability of 5C-CPT to distinguish between response inhibition and waiting impulsivity and allow symptom specific treatment.

show abstract

What are the benefits and harms of methylphenidate in children and adolescents with attention deficit hyperactivity disorder (ADHD)?

Burch¹,

Magalhães²,

PhD³

2016

Cochrane Clinical Answers

View full text Add to dashboard Cite

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)

Abstract: i Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review)

Cited by 18 publications

References 812 publications

Methylphenidate for Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) – unpublished or unregistered randomised clinical trials

Methylphenidate for Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) – unpublished or unregistered randomised clinical trials

The D1 receptor agonist SKF38393 improves waiting impulsivity in a baseline dependent manner

What are the benefits and harms of methylphenidate in children and adolescents with attention deficit hyperactivity disorder (ADHD)?

Contact Info

Product

Resources

About